Rush joins Parexel after serving as executive vice president and chief financial officer of Syneos Health, Inc. (formerly known as INC Research Holdings, Inc.) from August 2013 to August 2017.
Rush was previously senior vice president and CFO of Tekelec, a leading high-tech solutions and service provider that was acquired by Oracle.
He also held positions of increasing responsibility at Siebel Systems, Quintiles Transnational Holdings, PricewaterhouseCoopers and Ernst and Young. He is a Certified Public Accountant and has a Bachelor of Science in Business and a Master of Accounting from the University of North Carolina at Chapel Hill.
Fournier joined Parexel in 2014 and has served as the company's corporate vice president and interim chief human resources officer since January 2018. She will be responsible for working in partnership with Parexel's executive leaders to drive high performance and develop the company's people and growth strategies.
Prior to her current role, Fournier served as corporate vice president for compensation, benefits and HR M and A at Parexel.
Previously, Fournier held a variety of senior human resource leadership roles in the United States and abroad with companies including PTC, Cambridge Technology Partners, William M. Mercer and Medtronic. Fournier holds a Bachelor of Arts from the University of Michigan and is a Certified Compensation Professional.
Rush's appointment will be effective August 20, 2018 and Fournier's was effective August 2, 2018. Both will be based at Parexel's corporate headquarters in Waltham, Massachusetts.
Parexel International offers Phase I-IV clinical research, regulatory, consulting and market access services.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval